These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17563732)

  • 1. Multiple myeloma patients receiving pre-emptive donor lymphocyte infusion after partial T-cell-depleted allogeneic stem cell transplantation show a long progression-free survival.
    Levenga H; Levison-Keating S; Schattenberg AV; Dolstra H; Schaap N; Raymakers RA
    Bone Marrow Transplant; 2007 Aug; 40(4):355-9. PubMed ID: 17563732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
    Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM.
    Lokhorst HM; Segeren CM; Verdonck LF; van der Holt B; Raymakers R; van Oers MH; Barge RM; Schouten HC; Westveer PH; Steijaert MM; Cornelissen JJ; Sonneveld P;
    J Clin Oncol; 2003 May; 21(9):1728-33. PubMed ID: 12721248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of an intensified myeloablative conditioning regimen with in vivo T cell depletion followed by allografting in patients with advanced multiple myeloma.
    Kröger N; Einsele H; Derigs G; Wandt H; Krüll A; Zander A
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):861-4. PubMed ID: 20139025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
    Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).
    Kröger N; Einsele H; Wolff D; Casper J; Freund M; Derigs G; Wandt H; Schäfer-Eckart K; Wittkowsky G; Schmitz N; Krüger W; Zabelina T; Renges H; Ayuk F; Krüll A; Zander A;
    Bone Marrow Transplant; 2003 Jun; 31(11):973-9. PubMed ID: 12774047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
    Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
    Michallet AS; Nicolini F; Fürst S; Le QH; Dubois V; Hayette S; Bourgeot JP; Tremisi JP; Thomas X; Gebuhrer L; Michallet M
    Bone Marrow Transplant; 2005 Mar; 35(6):601-8. PubMed ID: 15756285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up.
    Shimoni A; Hardan I; Ayuk F; Schilling G; Atanackovic D; Zeller W; Yerushalmi R; Zander AR; Kroger N; Nagler A
    Cancer; 2010 Aug; 116(15):3621-30. PubMed ID: 20564132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High stem cell dose will not compensate for T cell depletion in allogeneic non-myeloablative stem cell transplantation.
    Passweg JR; Meyer-Monard S; Gregor M; Favre G; Heim D; Ebnoether M; Tichelli A; Gratwohl A
    Bone Marrow Transplant; 2002 Sep; 30(5):267-71. PubMed ID: 12209347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia.
    Kobbe G; Fenk R; Neumann F; Bernhardt A; Steidl U; Kondakci M; Graef T; Aivado M; Vaupel M; Huenerlituerkoglu AN; Kronenwett R; Pape H; Hildebrand B; Germing U; Haas R
    Cytotherapy; 2004; 6(6):533-42. PubMed ID: 15764020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma.
    Bruno B; Sorasio R; Patriarca F; Montefusco V; Guidi S; Busca A; Scimé R; Console G; Milone G; Marotta G; Dominietto A; Giaccone L; Rotta M; Falda M; Bacigalupo A; Bosi A; Corradini P; Fanin R; Pollichieni S; Boccadoro M;
    Eur J Haematol; 2007 Apr; 78(4):330-7. PubMed ID: 17331132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma.
    van de Donk NW; Kröger N; Hegenbart U; Corradini P; San Miguel JF; Goldschmidt H; Perez-Simon JA; Zijlmans M; Raymakers RA; Montefusco V; Ayuk FA; van Oers MH; Nagler A; Verdonck LF; Lokhorst HM
    Bone Marrow Transplant; 2006 Jun; 37(12):1135-41. PubMed ID: 16757975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow up of patients with multiple myeloma after high-dose chemotherapy and allogeneic stem cell transplantation.
    Rabitsch W; Prinz E; Ackermann J; Wöhrer S; Kaufmann H; Seidl S; Keil F; Kalhs P; Greinix H; Gisslinger H; Leitner G; Drach J
    Eur J Haematol; 2004 Jan; 72(1):26-31. PubMed ID: 14962259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short Report: Engraftment of T-cell-depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen.
    Craddock C; Bardy P; Kreiter S; Johnston R; Apperley J; Marks D; Huber C; Kolbe K; Goulding R; Lawler M; Goldman J; Hughes T; Derigs G
    Br J Haematol; 2000 Dec; 111(3):797-800. PubMed ID: 11122140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tandem autologous non-myeloablative allogeneic transplantation in patients with multiple myeloma relapsing after a first high dose therapy.
    Karlin L; Arnulf B; Chevret S; Ades L; Robin M; De Latour RP; Malphettes M; Kabbara N; Asli B; Rocha V; Fermand JP; Socie G
    Bone Marrow Transplant; 2011 Feb; 46(2):250-6. PubMed ID: 20400980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma.
    Eom KS; Min CK; Lee S; Kim YJ; Kim SY; Kim HJ; Lee JW; Min WS; Kim CC
    Jpn J Clin Oncol; 2006 Jul; 36(7):432-8. PubMed ID: 16782727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
    Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
    Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma.
    Schmidt-Hieber M; Blau IW; Trenschel R; Andreesen R; Stuhler G; Einsele H; Kanz L; Keilholz U; Marinets O; Beelen DW; Fauser AA; Volin L; Ruutu T; Uharek L; Fietz T; Knauf W; Hopfenmüller W; Thiel E; Freund M; Casper J
    Bone Marrow Transplant; 2007 Apr; 39(7):389-96. PubMed ID: 17310135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.